Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Bonora

Showing results (261-270 of 302) with videos related to

Pageof 31
Sort By:
Antibiotics (Basel, Switzerland)|September 28, 2023
Sequential or Combination Treatments as Rescue Therapies in Immunocompromised Patients with Persistent SARS-CoV-2 Infection in the Omicron Era: A Case SeriesBianca Maria Longo, Francesco Venuti, Alberto Gaviraghi, et al.
The Pharmacogenomics Journal|October 20, 2022
Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-studyRohan Gurjar, Laura Dickinson, Daniel Carr, et al.
Journal of Medical Virology|October 29, 2010
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practiceMattia C F Prosperi, Maurizio Zazzi, Grazia Punzi, et al.
AIDS (London, England)|March 15, 2019
Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapyAntonella Castagna, Stefano Rusconi, Roberto Gulminetti, et al.
Open Forum Infectious Diseases|July 30, 2025
Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered QuestionsAnna Maria Geretti, Marta Boffito, Stefano Bonora, et al.
Therapeutic Drug Monitoring|March 13, 2012
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatmentAntonio DʼAvolio, Alessia Ciancio, Marco Siccardi, et al.
The Journal of Antimicrobial Chemotherapy|August 8, 2006
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatmentStefano Aquaro, Roberta D'Arrigo, Valentina Svicher, et al.
The New Microbiologica|May 27, 2014
Less drug regimens and PI/r-based strategies in HIV infection: focus on best practices using the HIV patient's journey methodologySimone Marcotullio, Adriana Ammassari, Massimo Andreoni, et al.
Current HIV Research|July 16, 2009
Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patientsAnnalisa Saracino, Laura Monno, Alessandra Tartaglia, et al.
Plos One|December 19, 2017
Socioeconomic status and biomedical risk factors in migrants and native tuberculosis patients in ItalySilvia Pittalis, Pierluca Piselli, Silvia Contini, et al.
Pageof 31

Showing results (261-270 of 302) with videos related to

Sort By:
Pageof 31
Antibiotics (Basel, Switzerland)|September 28, 2023
Sequential or Combination Treatments as Rescue Therapies in Immunocompromised Patients with Persistent SARS-CoV-2 Infection in the Omicron Era: A Case SeriesBianca Maria Longo, Francesco Venuti, Alberto Gaviraghi, et al.
The Pharmacogenomics Journal|October 20, 2022
Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-studyRohan Gurjar, Laura Dickinson, Daniel Carr, et al.
Journal of Medical Virology|October 29, 2010
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practiceMattia C F Prosperi, Maurizio Zazzi, Grazia Punzi, et al.
AIDS (London, England)|March 15, 2019
Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapyAntonella Castagna, Stefano Rusconi, Roberto Gulminetti, et al.
Open Forum Infectious Diseases|July 30, 2025
Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered QuestionsAnna Maria Geretti, Marta Boffito, Stefano Bonora, et al.
Therapeutic Drug Monitoring|March 13, 2012
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatmentAntonio DʼAvolio, Alessia Ciancio, Marco Siccardi, et al.
The Journal of Antimicrobial Chemotherapy|August 8, 2006
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatmentStefano Aquaro, Roberta D'Arrigo, Valentina Svicher, et al.
The New Microbiologica|May 27, 2014
Less drug regimens and PI/r-based strategies in HIV infection: focus on best practices using the HIV patient's journey methodologySimone Marcotullio, Adriana Ammassari, Massimo Andreoni, et al.
Current HIV Research|July 16, 2009
Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patientsAnnalisa Saracino, Laura Monno, Alessandra Tartaglia, et al.
Plos One|December 19, 2017
Socioeconomic status and biomedical risk factors in migrants and native tuberculosis patients in ItalySilvia Pittalis, Pierluca Piselli, Silvia Contini, et al.
Pageof 31